https://ir.avalotx.com/ https://ir.avalotx.com/news-events-presentations/press-releases https://ir.avalotx.com/news-events-presentations/events https://ir.avalotx.com/news-events-presentations/presentations https://ir.avalotx.com/news-events-presentations/email-alerts https://ir.avalotx.com/analyst-coverage https://ir.avalotx.com/stock-data/quote-chart https://ir.avalotx.com/stock-data/historical-data https://ir.avalotx.com/sec-filings https://ir.avalotx.com/sec-filings/all-sec-filings https://ir.avalotx.com/sec-filings/annual-reports https://ir.avalotx.com/sec-filings/quarterly-reports https://ir.avalotx.com/sec-filings/section-16-filings https://ir.avalotx.com/corporate-governance/board-committees-governance-documents https://ir.avalotx.com/ir-resources/contacts https://ir.avalotx.com/ir-resources/faq https://ir.avalotx.com/news-events-presentations/press-releases/detail/218/avalo-therapeutics-reports-2025-financial-results-and-recent-business-updates 2026-03-24T09:48:39-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/217/avalo-therapeutics-to-participate-in-upcoming-investor-conferences 2026-02-24T07:00:02-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/216/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635c4 2026-02-18T16:05:03-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/215/avalo-therapeutics-to-participate-in-upcoming-investor-conferences 2026-02-04T07:00:06-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/214/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635c4 2025-11-17T16:30:02-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/213/avalo-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-updates 2025-11-06T07:01:11-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/212/avalo-therapeutics-to-participate-in-upcoming-investor-conferences 2025-11-03T07:00:08-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/211/avalo-therapeutics-announces-completion-of-enrollment-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment-of-hidradenitis-suppurativa 2025-10-29T07:00:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/210/avalo-therapeutics-expands-leadership-team-with-key-appointments-in-business-development-and-human-resources 2025-10-01T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/209/avalo-therapeutics-appoints-kevin-r-lind-to-board-of-directors 2025-09-22T07:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/208/avalo-therapeutics-to-participate-in-upcoming-investor-conferences 2025-08-27T07:00:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/207/avalo-reports-second-quarter-2025-financial-results-and-recent-business-updates 2025-08-07T07:00:28-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/206/avalo-therapeutics-to-participate-in-upcoming-investor-conferences 2025-06-23T07:00:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/205/avalo-therapeutics-announces-appointment-of-rita-jain-m-d-to-board-of-directors 2025-06-18T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/204/avalo-therapeutics-to-participate-in-upcoming-investor-conferences 2025-05-27T10:05:35-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/203/avalo-reports-first-quarter-2025-financial-results-and-recent-business-updates 2025-05-12T07:00:08-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/202/avalo-therapeutics-to-participate-in-the-citizens-life-sciences-conference 2025-04-30T07:00:20-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/201/avalo-therapeutics-appoints-michael-heffernan-as-chairman-of-the-board 2025-03-26T07:00:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/200/avalo-reports-2024-financial-results-and-recent-business-updates 2025-03-20T07:00:23-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/199/avalo-therapeutics-to-participate-in-upcoming-investor-conferences 2025-02-24T07:00:07-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/198/avalo-therapeutics-to-present-at-oppenheimers-35th-annual-healthcare-life-sciences-conference 2025-02-04T08:00:17-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/197/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer 2025-01-02T07:00:34-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/196/avalo-therapeutics-receives-69-4-million-in-proceeds-from-the-full-exercise-of-private-placement-warrants 2024-11-12T07:00:15-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/195/avalo-therapeutics-to-present-at-upcoming-investor-conferences 2024-11-11T07:00:13-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/194/avalo-reports-third-quarter-2024-financial-results-and-recent-business-updates 2024-11-07T07:00:28-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/193/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment-of-hidradenitis-suppurativa 2024-10-08T07:00:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/192/avalo-announces-participation-in-september-investor-conferences 2024-09-04T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/191/avalo-reports-second-quarter-2024-financial-results-and-provides-business-updates 2024-08-12T07:00:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/190/avalo-therapeutics-announces-appointment-of-dr-mittie-doyle-as-chief-medical-officer 2024-07-16T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/189/avalo-therapeutics-announces-active-ind-for-avtx-009-an-anti-il-1-mab-to-treat-hidradenitis-suppurativa 2024-07-09T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/188/avalo-therapeutics-announces-appointment-of-paul-varki-as-chief-legal-officer 2024-06-24T16:01:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/187/avalo-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit 2024-06-17T07:30:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/186/avalo-reports-first-quarter-2024-financial-results-and-provides-business-updates 2024-05-13T07:30:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/185/avalo-therapeutics-appoints-biotech-leaders-to-board-of-directors 2024-04-02T07:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/184/avalo-reports-2023-financial-results-and-provides-business-updates 2024-03-29T16:01:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/183/avalo-acquires-anti-il-1-mab-and-announces-private-placement-financing-of-up-to-185-million 2024-03-27T16:01:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/182/avalo-therapeutics-announces-1-for-240-reverse-stock-split 2023-12-27T07:00:02-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/181/avalo-encourages-stockholders-to-vote-for-the-reverse-stock-split 2023-12-07T07:00:02-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/180/avalo-reports-third-quarter-2023-financial-results-and-provides-business-updates 2023-11-09T07:00:08-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/179/avalo-completes-divestiture-of-avtx-800-series 2023-10-31T07:01:04-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/178/avalo-therapeutics-successfully-eliminates-35-million-debt-paving-the-way-for-future-growth-and-innovation 2023-09-26T07:00:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/177/avalo-enters-into-agreement-to-divest-avtx-800-series 2023-09-12T07:00:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/176/avalo-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference 2023-09-06T07:00:04-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/175/avalo-reports-second-quarter-2023-financial-results-and-provides-business-updates 2023-08-03T07:00:11-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/174/avalo-to-participate-in-svb-securities-therapeutics-forum 2023-07-06T16:01:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/173/avalo-announces-topline-data-from-phase-2-peak-trial-for-avtx-002-quisovalimab-in-patients-with-non-eosinophilic-asthma 2023-06-26T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/172/avalo-to-present-at-the-jefferies-healthcare-conference 2023-06-01T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/171/avalo-announces-appointment-of-michael-croft-ph-d-and-jeff-edelson-m-d-to-its-scientific-advisory-board 2023-05-22T07:00:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/170/avalo-to-present-at-ats-2023-respiratory-innovation-summit 2023-05-15T07:00:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/169/avalo-to-present-at-the-2023-rbc-capital-markets-global-healthcare-conference 2023-05-10T07:00:08-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/168/avalo-reports-first-quarter-2023-financial-results-and-provides-business-updates 2023-05-04T16:01:40-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/167/avalo-reports-2022-financial-results-andprovides-business-updates 2023-03-29T07:30:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/166/avalo-to-present-at-oppenheimers-33rd-annual-healthcare-conference 2023-03-07T07:00:27-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/165/avalo-therapeutics-inc-announces-pricing-of-15-million-public-offering-of-common-stock-and-warrants 2023-02-02T21:54:37-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/164/avalo-therapeutics-inc-announces-proposed-public-offering-of-common-stock-and-warrants 2023-02-02T16:01:45-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/163/avalo-announces-it-has-completed-targeted-enrollment-of-80-patients-in-phase-2-peak-trial-of-avtx-002-in-non-eosinophilic-asthma 2023-01-17T07:00:09-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/162/avalo-reports-third-quarter-2022-financial-results-andprovides-business-updates 2022-11-07T07:30:06-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/161/avalo-sells-economic-rights-to-previously-out-licensed-assets-for-5-million 2022-11-07T11:07:47-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/160/avalo-advances-btla-agonist-fusion-protein-avtx-008-to-ind-enabling-stage 2022-09-06T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/159/avalo-to-present-at-the-h-c-wainwright-global-investment-conference 2022-09-01T07:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/158/avalo-therapeutics-announces-board-changes 2022-08-11T16:01:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/157/avalo-reports-second-quarter-2022-financial-results-andprovides-business-updates 2022-08-04T07:30:14-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/156/avalo-therapeutics-announces-first-patient-dosed-in-the-avtx-803-pivotal-trial-ladder-for-the-treatment-of-leukocyte-adhesion-deficiency-type-ii-lad-ii 2022-08-02T07:30:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/155/avalo-therapeutics-transfers-anti-il-18-antibody-avtx-007-camoteskimab-to-apollo-therapeutics 2022-08-01T07:00:12-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/154/avalo-therapeutics-announces-one-for-twelve-reverse-stock-split 2022-07-06T16:05:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/152/avalo-therapeutics-announces-first-patient-dosed-in-the-phase-2-peak-trial-of-avtx-002-for-the-treatment-of-non-eosinophilic-asthma-nea 2022-05-18T07:30:04-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/151/avalo-to-present-at-the-h-c-wainwright-global-life-sciences-conference 2022-05-17T07:30:09-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/150/avalo-therapeutics-first-quarter-2022-financial-results-andbusiness-updates 2022-05-05T07:30:07-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/149/avalo-to-present-at-oppenheimers-32nd-annual-healthcare-conference 2022-03-08T07:00:04-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/148/avalo-therapeutics-reports-2021-financial-results-andprovides-business-updates 2022-03-02T07:30:13-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/147/avalo-therapeutics-announces-leadership-transition 2022-02-17T07:30:04-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/146/avalo-therapeutics-to-present-at-the-2022-bio-ceo-and-investor-conference 2022-02-07T16:01:03-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/145/avalo-therapeutics-appoints-stephen-smolinski-as-chief-commercial-officer 2022-01-10T19:58:58-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/144/avalo-reports-positive-phase-1b-results-for-avtx-002-in-moderate-to-severe-crohns-disease-patients-and-presents-additional-program-updates-at-2022-investor-event 2022-01-06T07:30:07-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/143/avalo-therapeutics-to-host-virtual-investor-day-on-january-6-2022 2021-12-16T07:30:06-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/142/avalo-appoints-two-new-independent-directors-to-its-board 2021-12-06T07:30:03-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/141/avalo-to-present-at-two-upcoming-conferences 2021-11-11T07:00:14-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/140/avalo-reports-third-quarter-2021-financial-results-and-provides-business-updates 2021-11-09T16:01:11-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/139/avalo-to-present-at-the-jefferies-virtual-next-generation-ibd-therapeutics-summit 2021-10-13T07:00:11-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/138/avalo-to-present-at-the-2021-cantor-virtual-global-healthcare-conference 2021-09-20T07:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/137/avalo-therapeutics-inc-announces-closing-of-a-31-5-million-public-offering-of-common-stock-including-proceeds-from-exercise-of-option-to-purchase-additional-shares 2021-09-17T09:11:50-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/136/avalo-therapeutics-inc-announces-pricing-of-27-5-million-public-offering-of-common-stock 2021-09-14T22:23:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/135/avalo-therapeutics-inc-announces-proposed-public-offering-of-common-stock 2021-09-14T16:01:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/134/avalo-therapeutics-inc-announces-corporate-name-change-from-cerecor-inc 2021-08-26T07:30:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and-provides-business-updates 2021-08-02T16:01:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/132/cerecor-announces-drawdown-of-10-million-tranche-under-its-debt-financing-agreement-with-horizon-technology-finance 2021-08-02T07:30:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/131/cerecor-announces-positive-initial-phase-1b-results-for-cerc-002-in-moderate-to-severe-crohns-disease-patients 2021-07-26T16:01:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/130/cerecor-licenses-immune-checkpoint-program-from-sanford-burnham-prebys-further-expanding-pipeline-of-immunology-and-immuno-oncology-targets 2021-06-23T07:30:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/129/cerecor-enters-into-35-million-debt-financing-agreement-with-horizon-technology-finance 2021-06-07T07:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/128/cerecor-to-participate-in-upcoming-investor-conferences 2021-05-17T07:00:11-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/127/cerecor-reports-first-quarter-2021-financial-results-and-provides-business-updates 2021-05-13T07:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/126/fda-grants-fast-track-designation-to-cerc-002-for-treatment-of-hospitalized-patients-with-covid-19 2021-05-11T07:00:07-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/125/cerecor-doses-first-patient-in-a-phase-1b-proof-of-concept-clinical-trial-of-cerc-007-for-the-treatment-of-adult-onset-stills-disease 2021-05-05T07:00:10-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/124/cerecor-announces-new-worldwide-license-agreement-with-kyowa-kirin-for-anti-light-antibody-cerc-002 2021-03-29T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/123/cerecor-reports-2020-financial-results-and-provides-business-updates 2021-03-31T10:57:00-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/122/cerecor-to-present-at-upcoming-investor-conferences 2021-03-04T07:00:07-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/121/cerecor-announces-cerc-002-significantly-reduced-respiratory-failure-and-mortality-in-phase-2-clinical-trial-in-patients-hospitalized-with-covid-19-ards 2021-03-02T07:00:10-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/120/cerecor-appoints-schond-l-greenway-as-chief-financial-officer 2021-03-01T07:00:10-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/119/cerecor-announces-fast-track-designation-for-cerc-803-for-the-treatment-of-leukocyte-adhesion-deficiency-type-ii 2021-02-02T07:00:04-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/118/cerecor-announces-proceeds-from-option-to-purchase-additional-shares-of-common-stock-bringing-public-offering-proceeds-to-40-7-million 2021-01-20T07:00:03-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/117/cerecor-inc-announces-closing-of-36-4-million-public-offering-of-common-stock-and-pre-funded-warrants 2021-01-12T16:01:04-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/116/cerecor-inc-announces-pricing-of-36-4-million-public-offering-of-common-stock-and-pre-funded-warrants 2021-01-07T22:03:22-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/115/cerecor-inc-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants 2021-01-07T16:01:23-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/114/cerecor-announces-successful-proof-of-concept-data-for-cerc-002-a-unique-light-neutralizing-antibody-in-patients-hospitalized-with-covid-19-ards 2021-01-05T07:00:02-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/113/cerecor-announces-fda-acceptance-of-investigational-new-drug-application-for-cerc-007-for-the-treatment-of-stills-disease 2020-12-22T13:00:00-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/112/cerecor-announces-first-patient-dosed-in-a-phase-1b-clinical-trial-of-cerc-007-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma 2020-12-16T07:00:02-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/111/cerecor-announces-fda-acceptance-of-investigational-new-drug-application-for-cerc-007-for-treatment-of-relapsed-or-refractory-multiple-myeloma 2020-12-08T07:00:01-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/110/cerecor-announces-fda-acceptance-of-investigational-new-drug-application-for-cerc-803-to-treat-leukocyte-adhesion-deficiency-type-ii 2020-12-01T07:00:06-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/109/cerecor-to-collaborate-with-frontiers-cdg-consortium-on-pivotal-trial-of-cerc-801-for-the-treatment-of-pgm1-cdg 2020-11-17T07:00:03-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/108/cerecor-reports-third-quarter-2020-financial-results-and-provides-business-update 2020-11-09T16:01:06-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/107/cerecor-appoints-gilla-kaplan-ph-d-to-the-board-of-directors 2020-10-12T07:00:07-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/106/cerecor-to-present-at-upcoming-investor-conferences 2020-09-10T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/105/cerecor-resumes-phase-1b-clinical-trial-of-cerc-002-for-the-treatment-of-severe-pediatric-onset-crohns-disease 2020-08-26T07:00:09-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/104/cerecor-announces-peer-reviewed-publication-highlighting-the-role-of-the-inflammatory-cytokine-light-in-covid-19-ards 2020-08-13T07:00:04-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/103/cerecor-reports-second-quarter-2020-financial-results-and-business-update 2020-08-06T07:00:18-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/102/cerecor-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference 2020-08-05T07:00:08-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/101/cerecor-receives-rare-pediatric-disease-designation-for-cerc-006-in-lymphatic-malformations 2020-08-04T11:59:32-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/100/cerecor-receives-orphan-drug-designation-for-cerc-006-in-lymphatic-malformations 2020-08-03T07:00:12-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/99/cerecor-announces-first-patient-enrolled-in-multicenter-proof-of-concept-study-evaluating-cerc-002-for-covid-19-ards 2020-07-21T07:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/98/cerecor-inc-announces-closing-of-37-95-million-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares 2020-06-11T13:30:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/97/cerecor-inc-announces-pricing-of-33000000-public-offering-of-common-stock 2020-06-09T09:05:00-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/96/cerecor-inc-announces-proposed-public-offering-of-common-stock 2020-06-08T16:01:07-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/95/cerecor-to-present-at-the-jefferies-virtual-healthcare-conference 2020-05-29T07:00:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in-covid-19-induced-ards 2020-05-28T07:00:11-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/93/cerecor-and-myriad-genetics-announce-that-levels-of-light-a-novel-cytokine-were-highly-correlated-with-disease-severity-and-mortality-in-covid-19-ards-biomarker-study 2020-05-26T07:00:08-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/92/cerecor-reports-q1-2020-results-and-update 2020-05-07T06:30:04-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/91/cerecor-announces-changes-to-board-of-directors 2020-04-24T13:45:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/90/cerecor-announces-exploration-of-the-role-of-an-inflammatory-cytokine-light-in-covid-19-patients-with-acute-lung-injury-leading-to-acute-respiratory-distress-syndrome 2020-03-26T06:30:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/89/cerecor-reports-2019-results 2020-03-11T06:30:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/88/cerecor-announces-appointment-of-h-jeffery-wilkins-md-as-chief-development-officer 2020-03-06T09:00:06-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/87/cerecor-and-aevi-genomic-medicine-complete-merger 2020-02-03T16:15:04-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/86/cerecor-to-acquire-aevi-genomic-medicine 2019-12-05T08:45:05-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/85/cerecor-reports-third-quarter-2019-results 2019-11-14T06:30:01-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/84/cerecor-announces-clinical-updates-on-cerc-301-and-cerc-802 2019-11-11T06:30:01-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/83/cerecor-closes-deal-to-sell-pediatric-portfolio 2019-11-04T06:30:00-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/82/cerecor-to-sell-pediatric-portfolio-to-aytu-bioscience 2019-10-14T06:30:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/81/cerecor-receives-fast-track-designation-from-fda-for-cerc-802-for-the-treatment-of-mannose-phosphate-isomerase-deficiency 2019-08-21T06:30:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/80/cerecor-reports-second-quarter-2019-results 2019-08-08T16:05:16-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/79/fda-accepts-ind-application-for-cerecors-investigational-drug-cerc-802-for-the-treatment-of-mpi-cdg 2019-07-29T06:30:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/78/cerecor-announces-first-patient-enrolled-in-cdg-first-trial 2019-07-15T06:30:10-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/77/cerecor-announces-positive-final-results-of-cerc-301-in-the-treatment-of-neurogenic-orthostatic-hypotension-oh 2019-07-01T06:30:06-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/76/cerecor-added-to-russell-3000-index 2019-06-28T06:30:45-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/75/cerecor-appoints-keith-schmidt-to-its-board-of-directors 2019-06-12T16:05:29-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/74/cerecor-set-to-join-russell-3000-index 2019-06-11T13:00:30-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/73/cerecor-reports-first-quarter-2019-results 2019-05-09T16:05:07-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/72/cerecor-announces-positive-phase-i-safety-data-for-cerc-801-in-healthy-volunteers 2019-04-29T06:30:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/71/cerecor-announces-positive-interim-results-of-cerc-301-in-the-treatment-of-neurogenic-orthostatic-hypotension-noh 2019-04-15T06:30:45-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/70/cerecor-announces-leadership-changes 2019-04-11T06:30:56-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/69/cerecor-reports-fourth-quarter-and-full-year-2018-results 2019-03-18T16:06:00-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/68/cerecor-announces-closing-of-10-0-million-bought-deal-of-common-stock 2019-03-11T09:16:35-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/67/cerecor-increases-previously-announced-bought-deal-of-common-stock-to-10-million 2019-03-06T06:05:18-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/66/cerecor-announces-8-million-bought-deal-offering 2019-03-05T17:31:38-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/65/cerecor-receives-fast-track-designation-from-fda-for-cerc-801-for-the-treatment-of-pgm1-deficiency 2019-02-19T08:27:17-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/64/cerecor-announces-cerc-301-granted-u-s-patent 2019-02-15T06:30:04-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/63/cerecor-announces-u-s-headquarters-move-intopharmaceutical-corridor-of-rockville-maryland 2019-01-28T06:30:04-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/62/fda-accepts-ind-application-for-cerecors-investigational-drug-cerc-801-for-the-treatment-of-pgm1-deficiency 2019-01-22T06:30:14-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/61/fda-grants-cerecors-three-substrate-replacement-therapies-orphan-drug-designation 2019-01-16T06:30:05-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/60/cerecor-reports-third-quarter-2018-results 2018-11-13T07:00:31-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/59/cerecor-announces-submission-of-three-orphan-drug-designation-requests-for-substrate-replacement-therapies-to-treat-congenital-disorders-of-glycosylation 2018-10-31T16:00:04-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/58/cerecor-receives-rare-pediatric-disease-designation-for-cerc-801-for-patients-with-inborn-error-of-metabolism 2018-10-30T16:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/57/cerecor-to-participate-in-upcoming-healthcare-conferences 2018-09-26T13:00:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/56/cerecor-to-acquire-ichorion-therapeutics 2018-09-25T06:30:04-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/55/cerecor-ceo-to-present-at-the-h-c-wainwright-global-investment-conference 2018-08-31T07:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/54/cerecor-reports-second-quarter-2018-financial-results 2018-08-09T06:30:09-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/53/cerecor-announcesfirst-patient-enrolled-in-phase-i-trial-for-neurogenic-orthostatic-hypotension-noh-in-parkinsons-disease 2018-08-01T06:30:04-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/52/cerecor-announces-expansion-of-leadership-team 2018-07-16T06:00:05-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/51/cerecor-reports-first-quarter-2018-financial-results 2018-05-11T08:15:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/50/cerecor-appoints-simon-pedder-to-its-board-of-directors 2018-04-09T08:00:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/49/cerecor-inc-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31-2017 2018-04-02T08:00:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/48/cerecor-appoints-peter-greenleaf-as-chief-executive-officer 2018-03-28T08:00:00-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/47/cerecor-to-acquire-avadel-pharmaceuticals-pediatric-assets 2018-02-12T09:07:00-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/46/cerecor-announces-leadership-changes 2017-11-17T08:30:01-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/45/cerecor-acquires-trx-pharmaceuticals 2017-11-17T08:15:00-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/44/cerecor-inc-reports-third-quarter-2017-financial-results 2017-11-06T08:15:01-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/43/cerecor-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement 2017-10-18T08:15:00-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/41/cerecor-inc-announces-retirement-of-dr-uli-hacksell-as-president-and-chief-executive-officer 2017-08-14T08:04:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/40/cerecor-inc-reports-second-quarter-2017-financial-results 2017-08-14T08:02:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/42/cerecor-announces-divestiture-of-cerc-501-to-janssen-pharmaceuticals-inc 2017-08-14T08:37:03-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/39/cerecor-to-present-at-the-american-society-for-clinical-psychopharmacology-conference 2017-05-30T08:30:42-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/38/cerecor-appoints-steven-boyd-and-peter-greenleaf-to-board-of-directors 2017-05-15T08:30:00-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/37/cerecor-inc-reports-first-quarter-2017-financial-results 2017-05-09T08:30:02-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/36/cerecor-reports-encouraging-topline-data-from-a-nih-sponsored-proof-of-concept-trial-of-cerc-501-in-treatment-resistant-depression 2017-05-01T08:30:00-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/35/cerecor-inc-closes-5-0-million-private-placement 2017-04-28T08:30:01-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/34/cerecor-inc-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31-2016 2017-03-14T09:37:26-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/33/cerecor-engages-suntrust-robinson-humphrey-to-assist-with-review-of-strategic-alternatives 2017-02-07T09:32:57-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/32/cerecor-announces-at-the-market-equity-offering-program 2017-01-27T16:20:27-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/31/cerecor-announces-top-line-results-from-cerc-501-phase-2-study-for-nicotine-withdrawal 2016-12-05T08:00:07-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study-for-major-depressive-disorder 2016-11-29T16:01:00-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/29/cerecor-inc-reports-third-quarter-2016-financial-results 2016-11-08T09:16:37-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/28/discovery-of-cerecor-drug-candidate-cerc-611-ly3130481-published-in-nature-medicine 2016-11-07T14:35:45-05:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/27/cerecor-to-present-at-the-15th-annual-bio-investor-forum-in-san-francisco-on-october-18th-2016 2017-10-23T18:15:45-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/26/cerecor-announces-acquisition-of-tarp-8-ampa-receptor-antagonist-cerc-611-from-lilly 2017-10-23T18:15:45-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/25/cerecor-announces-completion-of-enrollment-in-phase-2-clinical-trial-with-cerc-301-as-an-oral-adjunctive-treatment-of-major-depressive-disorder 2017-10-23T18:15:44-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/24/cerecor-enters-into-a-15-million-common-stock-purchase-agreement-with-aspire-capital-fund-llc 2017-10-23T18:15:44-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/23/cerecor-announces-last-patient-enrolled-in-phase-2-clinical-trial-with-cerc-501-for-smoking-cessation 2017-10-23T18:15:44-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/22/cerecor-to-present-at-23rd-annual-newsmakers-in-the-biotech-industry-conference-in-new-york-city-september-9-2016 2017-10-23T18:15:43-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/21/cerecor-inc-announces-initiation-of-second-cerc-501-phase-2-clinical-trial-in-smokers 2017-10-23T18:15:43-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/20/cerecor-to-present-at-the-18th-annual-rodman-renshaw-global-investment-conference-in-new-york-city-september-11-13th-2016 2017-10-23T18:15:43-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/19/cerecor-inc-reports-second-quarter-2016-financial-results 2017-10-23T18:15:42-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/18/cerecor-announces-research-grant-from-the-department-of-defense-to-study-cerc-501-in-animal-models-for-co-morbid-post-traumatic-stress-disorder-and-alcohol-use-disorder 2017-10-23T18:15:42-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/17/cerecor-announces-1-0-million-research-development-grant-from-the-national-institute-on-alcohol-abuse-and-alcoholism-at-the-national-institutes-of-health 2017-10-23T18:15:41-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/16/cerecor-inc-reports-first-quarter-2016-financial-results 2017-10-23T18:15:41-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/15/cerecor-announces-1-0-million-research-development-grant-from-the-national-institute-on-drug-abuse-nida-at-the-national-institutes-of-health 2017-10-23T18:15:40-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/14/cerecor-inc-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31-2015 2017-10-23T18:15:40-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/13/cerecor-inc-to-present-at-the-roth-conference-on-march-16th 2017-10-23T18:15:40-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/12/cerecor-to-host-rd-day-in-new-york-city-on-march-1-2016 2017-10-23T18:15:39-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/11/cerecor-announces-initiation-of-phase-2-clinical-trial-with-cerc-501-for-smoking-cessation 2017-10-23T18:15:39-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/10/cerecor-inc-to-present-at-the-bio-ceo-investor-conference-in-new-york-city 2017-10-23T18:15:38-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/9/cerecor-announces-publication-describing-antidepressant-activity-of-cerc-301-in-preclinical-model 2017-10-23T18:15:38-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/8/cerecor-inc-appoints-thomas-aasen-to-board-of-directors 2017-10-23T18:15:38-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/7/cerecor-inc-to-present-at-biotech-showcase-2016-in-san-francisco 2017-10-23T18:15:37-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/6/cerecor-inc-names-uli-hacksell-chairman-of-cerecor-and-former-ceo-of-acadia-as-president-and-ceo 2017-10-23T18:15:37-04:00 https://ir.avalotx.com/news-events-presentations/press-releases/detail/5/publication-reports-human-brain-penetration-and-target-engagement-of-cerecors-oral-kappa-opioid-receptor-antagonist-cerc-501 2017-10-23T18:15:36-04:00 https://ir.avalotx.com/news-events-presentations/events/detail/20260310-leerink-partners-global-healthcare-conference 2026-02-24T07:00:52-05:00 https://ir.avalotx.com/news-events-presentations/events/detail/20260303-td-cowen-annual-healthcare-conference 2026-02-24T07:00:41-05:00 https://ir.avalotx.com/news-events-presentations/events/detail/20260225-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-04T07:05:22-05:00 https://ir.avalotx.com/news-events-presentations/events/detail/20260211-guggenheim-emerging-outlook-biotech-summit-2026 2026-02-04T07:05:09-05:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001950047-26-003175/primary_doc.html 2026-04-01T16:49:25-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001677036-26-000002/form4-04012026_040408.html 2026-04-01T16:06:09-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001707797-26-000003/form4-04012026_040410.html 2026-04-01T16:06:00-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0000935836-26-000188/primary_doc.html 2026-04-01T13:03:25-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0002017156-26-000002/form4-03312026_080309.html 2026-03-31T16:17:36-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001862734-26-000002/form4-03312026_080342.html 2026-03-31T16:16:00-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001247024-26-000002/form4-03312026_080359.html 2026-03-31T16:15:49-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001810417-26-000004/form4-03312026_080330.html 2026-03-31T16:15:39-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001586785-26-000004/form4-03312026_080315.html 2026-03-31T16:15:29-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0002013869-26-000002/form4-03312026_080309.html 2026-03-31T16:14:56-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001789335-26-000004/form4-03312026_080349.html 2026-03-31T16:13:16-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001534120-26-000016/avtx-20260323.htm 2026-03-27T16:02:41-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001104659-26-032997/tm268193d1_s8.htm 2026-03-23T07:16:04-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001534120-26-000011/avtx-20251231.htm 2026-03-23T07:04:43-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001534120-26-000010/avtx-20260323.htm 2026-03-23T07:01:57-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001918845-26-000004/form4-03182026_080310.html 2026-03-18T16:08:00-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0001950047-26-002672/primary_doc.html 2026-03-16T16:39:55-04:00 https://ir.avalotx.com/sec-filings/all-sec-filings/content/0000315066-26-000651/primary_doc.html 2026-03-06T10:05:59-05:00 https://ir.avalotx.com/privacy-policy https://ir.avalotx.com/disclaimer https://ir.avalotx.com/sitemap